IXICO plc Notice of Results (5810E)
09 Novembre 2020 - 08:00AM
UK Regulatory
TIDMIXI
RNS Number : 5810E
IXICO plc
09 November 2020
IXICO plc
("IXICO" or the "Company")
Notice of results
Analyst and Investor briefings
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, will announce its audited Final Results
for the year ended 30 September 2020 on Wednesday 2 December
2020.
Analyst briefing
A briefing open to analysts will take place remotely via video
conference call on Wednesday 2 December 2020 at 1.00pm (GMT). If
you would like the details of this call please contact Walbrook PR
on ixico@walbrookpr.com
Investor briefing
IXICO plc will be hosting a live online presentation open to all
investors on Wednesday 2 December at 3.30pm (GMT). The presentation
will be delivered by Giulio Cerroni, Chief Executive Officer, Grant
Nash, Chief Financial Officer and Lammert Albers, Chief Commercial
Officer. The Company is committed to providing an opportunity for
all existing and potential investors to hear directly from
management on the recent developments and additionally providing an
update on the business. The presentation will be hosted through the
digital platform Investor Meet Company.
Investors can sign up to Investor Meet Company for free and add
to meet IXICO plc via the following link:
https://www.investormeetcompany.com/ixico-plc/register-investor
For those investors who have already registered and added to
meet the Company, they will automatically be invited. Questions can
be submitted pre-event via your Investor Meet Company dashboard or
in real time during the presentation, via the "Ask a Question"
function. Whilst the Company may not be in a position to answer
every question it receives, it will aim to address the most
prominent within the confines of information already disclosed to
the market through regulatory notifications. A recording of the
presentation, a PDF of the slides used, and responses to the
Q&A session will be available on the Investor Meet Company
platform afterwards.
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBRBDBSDGDGGL
(END) Dow Jones Newswires
November 09, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Ixico (LSE:IXI)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Ixico (LSE:IXI)
Storico
Da Mar 2023 a Mar 2024